Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci - LARVOL DELTA

IGHID12334: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding (clinicaltrials.gov) - P=N/A | N=36000 | Active, not recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=788 | Completed | Sponsor: Liverpool School of Tropical Medicine | Active, not recruiting ➔ Completed

Trial completion • Anemia • Hematological Disorders • Infectious Disease • Malaria

SPARTAN: The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy (clinicaltrials.gov) - P4 | N=160 | Completed | Sponsor: Infectious Diseases Research Collaboration, Uganda | Recruiting ➔ Completed | N=120 ➔ 160 | Trial completion date: Apr 2026 ➔ Nov 2025

Enrollment change • Trial completion • Trial completion date • Infectious Disease • Malaria

Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: Walter Reed Army Institute of Research (WRAIR)

New trial • Infectious Disease

Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Curtin University

New P4 trial • Infectious Disease • Malaria

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=1000 | Active, not recruiting | Sponsor: Liverpool School of Tropical Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Anemia • Hematological Disorders • Infectious Disease • Malaria

IGHID12334: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding (clinicaltrials.gov) - P=N/A | N=36000 | Active, not recruiting | Sponsor: University of North Carolina, Chapel Hill | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Malaria

IGHID12334: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding (clinicaltrials.gov) - P=N/A | N=36000 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

IGHID12334: IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding (clinicaltrials.gov) - P=N/A | N=36000 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill

New trial • Infectious Disease • Malaria

Falciparum malaria in a child from Ghana with neutrophils showing phagocytosis of trophozoites, merozoites and possibly schizont. (PubMed, Parasitol Int) - "Both children were treated successfully with piperaquine tetraphosphate/artenimol (Eurartesim®)...While the findings highlight the role of phagocytosis in parasite clearance, the absence of similar observations in the second twin raises questions about individual immune responses and genetic factors. Further research is needed to explore the underlying biological mechanisms."

Journal • CNS Disorders • Hematological Disorders • Infectious Disease • Inflammation • Malaria • Pain • Psychiatry • Schizophrenia

Dihydroartemisinin-Piperaquine Combination in the Treatment of Uncomplicated Plasmodium falciparum Malaria: Update on Clinical Failures in Africa and Tools for Surveillance. (PubMed, J Clin Med) - "However, some therapeutic failures with this combination remain unexplained by strains' characterization. We provide an overview on the use of dihydroartemisinin-piperaquine in malaria treatment and discuss tools available to monitor its efficacy."

Journal • Review • Infectious Disease • Malaria

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=1000 | Recruiting | Sponsor: Liverpool School of Tropical Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Hematological Disorders • Infectious Disease • Malaria

SPARTAN: The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Infectious Diseases Research Collaboration, Uganda | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Infectious Disease • Malaria

SPARTAN: The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: Infectious Diseases Research Collaboration, Uganda

Combination therapy • New P4 trial • Infectious Disease • Malaria

A high-throughput LC-MS/MS assay for piperaquine from dried blood spots: Improving malaria treatment in resource-limited settings. (PubMed, J Mass Spectrom Adv Clin Lab) - "A sensitive LC-MS/MS method, in combination with fully automated extraction in a 96-well plate format, was developed and validated for the quantification of piperaquine in DBS. The assay was implemented in a bioanalytical laboratory for processing large-scale clinical trial samples."

Journal • Infectious Disease • Malaria

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: Liverpool School of Tropical Medicine

New P4 trial • Anemia • Hematological Disorders • Infectious Disease • Malaria

Comparing Chemoprevention Drugs for School-based Malaria Control (clinicaltrials.gov) - P4 | N=646 | Completed | Sponsor: University of Maryland, Baltimore

New P4 trial • Anemia • Hematological Disorders • Infectious Disease • Malaria

Comparing Chemoprevention Approaches for School-based Malaria Control (clinicaltrials.gov) - P4 | N=746 | Completed | Sponsor: University of Maryland, Baltimore | Enrolling by invitation ➔ Completed

Trial completion • Anemia • Hematological Disorders • Infectious Disease • Malaria

"If the patient is unable to swallow or fulfills criteria for severe malaria, IV artesunate. Otherwise, in Italy Eurartesim would be the first choice for non-severe falciparum." (,@AlbertoEMaraolo)

Clinical • Infectious Disease • Malaria

DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (clinicaltrials.gov) - P4 | N=190 | Completed | Sponsor: University of California, San Francisco | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Apr 2022

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease

Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials (clinicaltrials.gov) - P2/3 | N=182 | Active, not recruiting | Sponsor: Johns Hopkins Bloomberg School of Public Health | Trial completion date: Apr 2021 ➔ Nov 2022

Combination therapy • Trial completion date • Infectious Disease • Malaria

Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon (clinicaltrials.gov) - P4 | N=184 | Not yet recruiting | Sponsor: University of Yaounde 1

New P4 trial • Infectious Disease • Malaria • ABCB1

Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Karamoja Region, Uganda (clinicaltrials.gov) - P4 | N=7194 | Not yet recruiting | Sponsor: Malaria Consortium

New P4 trial • Infectious Disease • Malaria

DMA: Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy (clinicaltrials.gov) - P3 | N=511 | Completed | Sponsor: University of Oxford | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Infectious Disease • Malaria

DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (clinicaltrials.gov) - P4 | N=190 | Recruiting | Sponsor: University of California, San Francisco | Trial primary completion date: Dec 2021 ➔ Apr 2022

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease